The estimated Net Worth of Marc Stapley is at least $18.9 Миллион dollars as of 15 August 2024. Mr. Stapley owns over 6,250 units of Glaukos stock worth over $5,060,913 and over the last 13 years he sold GKOS stock worth over $13,611,753. In addition, he makes $249,758 as Independent Director at Glaukos.
Marc has made over 49 trades of the Glaukos stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 6,250 units of GKOS stock worth $200,000 on 15 August 2024.
The largest trade he's ever made was buying 60,000 units of Glaukos stock on 10 June 2022 worth over $979,800. On average, Marc trades about 2,612 units every 41 days since 2012. As of 15 August 2024 he still owns at least 40,326 units of Glaukos stock.
You can see the complete history of Mr. Stapley stock trades at the bottom of the page.
Marc A. Stapley serves as Independent Director of the Company. Mr. Stapley is currently the executive vice president, strategy and corporate development, for Illumina, Inc. Previously, Mr. Stapley served as Illumina's chief administrative officer with responsibility for all general and administrative functions. Prior to that, he served as senior vice president and chief financial officer of Illumina. He is also a member of Illumina’s executive management team, which is responsible for directing all aspects of the company’s strategy, planning and operations. Before joining Illumina, from 2009 to 2012, Mr. Stapley was senior vice president, finance at Pfizer Inc. and was responsible for global financial processes and systems, leading integration efforts in both the Wyeth Ltd. and King Pharmaceutical, Inc. acquisitions and providing oversight to the company’s largest technology investment program. Prior to Pfizer, he served in a variety of senior finance roles at Alcatel-Lucent, including Americas chief financial officer. He also worked as finance director and controller for several groups at Cadence Design Systems, Inc. Mr. Stapley is currently a member of the board of directors of Helix, Illumina's consumer genomics venture. Mr. Stapley began his career as an Auditor at Coopers & Lybrand. He holds a First Class B.Sc. (Honors) from The University of Reading (England) and is a member of the Institute of Chartered Accountants in England and Wales.
As the Independent Director of Glaukos, the total compensation of Marc Stapley at Glaukos is $249,758. There are 7 executives at Glaukos getting paid more, with Thomas Burns having the highest compensation of $5,716,560.
Marc Stapley is 50, he's been the Independent Director of Glaukos since 2014. There are 9 older and 2 younger executives at Glaukos. The oldest executive at Glaukos Corporation is William Link, 74, who is the Independent Chairman of the Board.
Marc's mailing address filed with the SEC is 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 11 years, insiders at Glaukos have traded over $300,254,118 worth of Glaukos stock and bought 17,376 units worth $317,262 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Gilbert H Kliman и Jonathan Silverstein. On average, Glaukos executives and independent directors trade stock every 25 days with the average trade being worth of $8,240,079. The most recent stock trade was executed by Gilbert H Kliman on 9 September 2024, trading 3,000 units of GKOS stock currently worth $96,000.
glaukos corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. glaukos has pioneered micro-invasive glaucoma surgery, or migs, to revolutionize the traditional glaucoma treatment and management paradigm. the company launched the istent trabecular micro-bypass stent, its first migs device, in the united states in 2012. glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. glaukos believes the istent is the smallest medical device ever approved by the food and drug administration, or fda, measuring 1.0 mm long and 0.33 mm wide. in june 2015, the company completed an initial public offering and its shares are now traded on the new york stock exchange unde
Glaukos executives and other stock owners filed with the SEC include: